Associated Papers
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
40359938 (PubMed )
Supplement: mmc6.xlsx › Sheet_1
Discovering Deleterious Single Nucleotide Polymorphisms of Human AKT1 Oncogene: An In Silico Study.
Zhang R et al.
Life (basel, Switzerland), 2023
37511907 (PubMed )
Supplement: life-13-01532-s001.zip › Supplementary_Table_S4.pdf
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
35512388 (PubMed )
Supplement: btac306_supplementary_data.zip › Supplementary_files.zip › Supplementary_files › Supplementary_file_7.xlsx › Sheet1
AKT mutant allele-specific activation dictates pharmacologic sensitivities.
Shrestha Bhattarai T et al.
Nature Communications, 2022
Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
Nagakubo Y et al.
Bmc Medical Genomics, 2019
A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.
Tyran M et al.
Cancers, 2019
Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F et al.
Oncotarget, 2016
27028851 (PubMed )
Supplement: oncotarget-07-27208-s001.pdf
Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
Clynick B et al.
The Journal of Molecular Diagnostics : Jmd, 2015
Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach.
Vuong H et al.
Genome Medicine, 2014
25360158 (PubMed )
Supplement: 13073_2014_81_MOESM1_ESM.xlsx › Table_S1
Select a paper to view details